Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 168

Results For "therapy"

1752 News Found

RenovoRx receives New 510(k) clearance from US FDA
News | September 08, 2021

RenovoRx receives New 510(k) clearance from US FDA

The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours


Sanofi buys Kadmon to grow its transplant business
Biotech | September 08, 2021

Sanofi buys Kadmon to grow its transplant business

It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)


Indian Pharmaceutical Market grew by 17.7 per cent in August
News | September 07, 2021

Indian Pharmaceutical Market grew by 17.7 per cent in August

Ind-Ra expects IPM revenue to grow over 12% YoY in FY22


Max Ventilator forms partnership with US-based Amptron Medical
Drug Approval | September 07, 2021

Max Ventilator forms partnership with US-based Amptron Medical

Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.


Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19
Drug Approval | September 06, 2021

Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19

Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence


Govt revises NLEM and slashes prices of 39 drugs
Policy | September 04, 2021

Govt revises NLEM and slashes prices of 39 drugs

At present 18 per cent of the local pharmaceutical market is under government's price control


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.


Covid-19 vaccine clinical trial for people with autoimmune disease
Drug Approval | September 03, 2021

Covid-19 vaccine clinical trial for people with autoimmune disease

Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study


Granules India receive DRDO licence to manufacture and market 2-DG
News | September 02, 2021

Granules India receive DRDO licence to manufacture and market 2-DG

The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19


Natco Pharma launch Nat-Lenalidomide in Canada
Drug Approval | September 02, 2021

Natco Pharma launch Nat-Lenalidomide in Canada

Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)